JP2022519019A5 - - Google Patents
Info
- Publication number
- JP2022519019A5 JP2022519019A5 JP2021541152A JP2021541152A JP2022519019A5 JP 2022519019 A5 JP2022519019 A5 JP 2022519019A5 JP 2021541152 A JP2021541152 A JP 2021541152A JP 2021541152 A JP2021541152 A JP 2021541152A JP 2022519019 A5 JP2022519019 A5 JP 2022519019A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- smg
- smu
- sm5c
- oligonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025060960A JP2025107175A (ja) | 2019-02-01 | 2025-04-02 | オリゴヌクレオチド組成物及びその方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800409P | 2019-02-01 | 2019-02-01 | |
| US62/800,409 | 2019-02-01 | ||
| US201962911335P | 2019-10-06 | 2019-10-06 | |
| US62/911,335 | 2019-10-06 | ||
| PCT/US2020/015971 WO2020160336A1 (en) | 2019-02-01 | 2020-01-30 | Oligonucleotide compositions and methods thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025060960A Division JP2025107175A (ja) | 2019-02-01 | 2025-04-02 | オリゴヌクレオチド組成物及びその方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519019A JP2022519019A (ja) | 2022-03-18 |
| JP2022519019A5 true JP2022519019A5 (enExample) | 2023-02-08 |
| JP7661228B2 JP7661228B2 (ja) | 2025-04-14 |
Family
ID=71840465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541152A Active JP7661228B2 (ja) | 2019-02-01 | 2020-01-30 | オリゴヌクレオチド組成物及びその方法 |
| JP2025060960A Pending JP2025107175A (ja) | 2019-02-01 | 2025-04-02 | オリゴヌクレオチド組成物及びその方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025060960A Pending JP2025107175A (ja) | 2019-02-01 | 2025-04-02 | オリゴヌクレオチド組成物及びその方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220098585A1 (enExample) |
| EP (1) | EP3917497A4 (enExample) |
| JP (2) | JP7661228B2 (enExample) |
| KR (1) | KR20210121199A (enExample) |
| CN (1) | CN113423385A (enExample) |
| AU (2) | AU2020216186C1 (enExample) |
| BR (1) | BR112021014940A2 (enExample) |
| CA (1) | CA3126845A1 (enExample) |
| IL (1) | IL284882A (enExample) |
| MA (1) | MA54875A (enExample) |
| MX (1) | MX2021009178A (enExample) |
| SG (1) | SG11202107318YA (enExample) |
| TW (2) | TW202526020A (enExample) |
| WO (1) | WO2020160336A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| IL320434A (en) | 2015-07-22 | 2025-06-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods |
| CN108779132B (zh) | 2016-03-13 | 2022-04-15 | 波涛生命科学有限公司 | 用于亚磷酰胺和寡核苷酸合成的组合物和方法 |
| JP2019520339A (ja) | 2016-06-03 | 2019-07-18 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド、その組成物および方法 |
| WO2017220751A1 (en) | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| CN110352244B (zh) | 2016-09-01 | 2023-03-21 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
| US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| JP2020522510A (ja) | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| CA3065523A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11718638B2 (en) | 2017-06-21 | 2023-08-08 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| EP3664816A4 (en) | 2017-08-08 | 2021-05-19 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES |
| CA3072110A1 (en) | 2017-09-18 | 2019-03-21 | Wave Life Sciences Ltd. | Technologies for oligonucleotide preparation |
| EP3694530A4 (en) | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| WO2019157531A1 (en) | 2018-02-12 | 2019-08-15 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| SG11202009877XA (en) | 2018-04-12 | 2020-11-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
| US12391942B2 (en) | 2018-05-11 | 2025-08-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| JP2022525541A (ja) | 2019-03-20 | 2022-05-17 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド調製に有用な技術 |
| AU2020395113A1 (en) | 2019-12-02 | 2022-06-09 | Shape Therapeutics Inc. | Therapeutic editing |
| EP4314296A2 (en) | 2021-03-29 | 2024-02-07 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
| EP4423272A2 (en) * | 2021-10-29 | 2024-09-04 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
| EP4479535A1 (en) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| US20260027237A1 (en) | 2022-07-15 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| JP2025524566A (ja) | 2022-07-15 | 2025-07-30 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | Ａｄａｒ媒介ｒｎａ編集のためのオリゴヌクレオチドおよびその使用 |
| AU2023321711A1 (en) * | 2022-08-11 | 2025-02-20 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| EP4689110A1 (en) | 2023-03-24 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| EP4688143A1 (en) | 2023-03-27 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of liver disease |
| TW202516003A (zh) | 2023-06-16 | 2025-04-16 | 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ | 用於治療神經退化性疾病之反義寡核苷酸 |
| WO2025030155A1 (en) * | 2023-08-03 | 2025-02-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2176256A1 (en) * | 1993-11-16 | 1995-05-26 | Lyle John Arnold, Jr. | Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages |
| WO2010118263A1 (en) * | 2009-04-08 | 2010-10-14 | University Of Massachusetts | Single-nucleotide polymorphism (snp) targeting therapies for the treatment of huntington's disease |
| CA2789038A1 (en) * | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| US10202599B2 (en) * | 2011-08-11 | 2019-02-12 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| EP3459549B1 (en) * | 2012-10-12 | 2022-04-06 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| RU2708237C2 (ru) * | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
| IL320434A (en) * | 2015-07-22 | 2025-06-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods |
| EP3452596A4 (en) * | 2016-05-04 | 2020-03-18 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
| EP3664816A4 (en) * | 2017-08-08 | 2021-05-19 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES |
-
2020
- 2020-01-30 CN CN202080011722.0A patent/CN113423385A/zh active Pending
- 2020-01-30 AU AU2020216186A patent/AU2020216186C1/en active Active
- 2020-01-30 WO PCT/US2020/015971 patent/WO2020160336A1/en not_active Ceased
- 2020-01-30 MA MA054875A patent/MA54875A/fr unknown
- 2020-01-30 KR KR1020217027787A patent/KR20210121199A/ko active Pending
- 2020-01-30 US US17/426,511 patent/US20220098585A1/en active Pending
- 2020-01-30 SG SG11202107318YA patent/SG11202107318YA/en unknown
- 2020-01-30 BR BR112021014940-6A patent/BR112021014940A2/pt unknown
- 2020-01-30 CA CA3126845A patent/CA3126845A1/en active Pending
- 2020-01-30 EP EP20748395.9A patent/EP3917497A4/en active Pending
- 2020-01-30 MX MX2021009178A patent/MX2021009178A/es unknown
- 2020-01-30 JP JP2021541152A patent/JP7661228B2/ja active Active
- 2020-01-31 TW TW114105751A patent/TW202526020A/zh unknown
- 2020-01-31 TW TW109103034A patent/TWI877133B/zh active
-
2021
- 2021-07-15 IL IL284882A patent/IL284882A/en unknown
-
2025
- 2025-04-02 JP JP2025060960A patent/JP2025107175A/ja active Pending
-
2026
- 2026-01-14 AU AU2026200223A patent/AU2026200223A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022519019A5 (enExample) | ||
| JP2025165976A5 (enExample) | ||
| JP2021074021A5 (enExample) | ||
| JP2025041652A5 (enExample) | ||
| EP3324978A1 (en) | Oligonucleotide compositions and methods thereof | |
| JP7348922B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2019534009A5 (enExample) | ||
| JP2022513719A5 (enExample) | ||
| EP3523437A1 (en) | Oligonucleotide compositions and methods thereof | |
| JP2016530882A5 (enExample) | ||
| JP2021522800A5 (enExample) | ||
| JP2018525357A5 (enExample) | ||
| JPH05505101A (ja) | オリゴヌクレオチド療法における三重らせん形成 | |
| BR112020018902A2 (pt) | oligonucleotídeo antissenso com toxicidade reduzida | |
| FR2931824A1 (fr) | Procede de synthese d'arn par voie chimique. | |
| JP2022524435A5 (enExample) | ||
| JP7164540B2 (ja) | 立体的に規定されたホスホロチオエートオリゴヌクレオチドの調製のための直交保護基 | |
| CN105121452A (zh) | 三环核苷和由其制备的寡聚化合物 | |
| JP2021511072A5 (enExample) | ||
| JP2024541771A5 (enExample) | ||
| Koch et al. | Locked nucleic acid | |
| JP2025518487A5 (enExample) | ||
| JP7198768B2 (ja) | ＵｎｙＬｉｎｋｅｒ迅速切断方法 | |
| JP2025511183A5 (enExample) | ||
| JP2024542738A5 (enExample) |